No CrossRef data available.
Article contents
Establishing cost-effectiveness of antipsychotic drugs
Published online by Cambridge University Press: 03 January 2018
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS000712500026008X/resource/name/firstPage-S000712500026008Xa.jpg)
- Type
- Columns
- Information
- Copyright
- Copyright © 1997 The Royal College of Psychiatrists
References
Adams, C. E., Soares, K. (1997) The Cochrane Collaboration and the process of systematic reviewing. Advances in Psychiatric Treatment, 3, 240–246.Google Scholar
Kennedy, E., Song, F., Hunter, R., et al (1997) Risperidone for schizophrenia. The Cochrane Library (CD-ROM). The Cochrane Collaboration; Issue 3. Oxford: Update Software.Google Scholar
Robert, G. & Kennedy, P. (1997) Establishing cost-effectiveness of atypical neuroleptics. British Journal of Psychiatry, 171, 103–104.Google Scholar
Wahlbeck, K., Cheine, M., Essali, M. A., et al (1997) Clozapine vs ‘typical’ neuroleptic medication for schizophrenia. The Cochrane Library (CD-ROM). The Cochrane Collaboration; Issue 3. Oxford: Update Software.Google Scholar
eLetters
No eLetters have been published for this article.